INTRODUCTION {#S5}
============

The dual-specificity tyrosine-phosphorylation-regulated kinase (DYRK) family of protein kinases are conserved across species from lower eukaryotes to mammals.^[@R1]^ DYRK family members are activated by autophosphorylating a tyrosine residue in their activation loop.^[@R2]^ DYRK1A is the most extensively characterized member of the DYRK family, which in humans, is encoded by the *DYRK1A* gene located in the Down syndrome critical region of chromosome 21.^[@R3]^ A growing body of literature implicates a strong causal relationship between *DYRK1A* haploinsufficiency and a recognizable syndrome known as *DYRK1A*-related intellectual disability syndrome.^[@R3]-[@R5]^ In addition to intellectual disability (ID), other frequently occurring features include: intrauterine growth restriction (IUGR), difficulty feeding (DF) with failure to thrive (FTT), microcephaly, seizures, dysmorphic facial features, and developmental delays (DD),^[@R5]^ while additional phenotypic features are observed less commonly.^[@R5],[@R6]^ Although many features of this syndrome are well-characterized; the full phenotypic spectrum has yet to be defined. This manuscript presents a cohort of individuals with *de novo* (when both parental samples available) *DYRK1A* single nucleotide variants (SNVs) or small deletions ≤10 base pairs and defines CAKUT/GD that have not been previously described in patients with *DYRK1A* syndrome. We also provide supporting evidence, using *Xenopus* embryos as a model, that *DYRK1A,* which is expressed in embryonic nephrons, is required for GU development and that two pathogenic variants of human *DYRK1A* are likely responsible for the CAKUT/GD phenotype. Together, these findings support the investigation of potential CAKUT/GD in the clinical workup of patients with *DYRK1A*-related ID syndrome.

MATERIALS AND METHODS {#S6}
=====================

Study participants {#S7}
------------------

The index patient was seen in the Renal Genetics Clinic (RGC) at Texas Children's Hospital (TCH). Subsequently, patients who had ES in a clinical diagnostic laboratory \[Baylor Genetics (BG)\] were queried for *de novo* (except P1, P12 and P15) pathogenic \[except P10 (likely pathogenic), P5, P7, and P17 called as VUS in the initial report\] variants in *DYRK1A*. Inclusion criteria also included: 1) variant confirmation using Sanger sequencing, and 2) lack of other variants that could explain the phenotype observed. Exclusion criteria included multiple additional candidate genes that may be related to the phenotype. The final size of our cohort after applying those filters is 19 patients. Clinical phenotype information was collected from initial ES requisition form or contacting referring physicians. The Institutional Review Board approved the study protocol for the Protection of Human Subjects at Baylor College of Medicine. Consent was obtained for clinical genetic testing/exome sequencing from each family participating in this study.

ES and data analysis {#S8}
--------------------

ES was performed by previously published methods at BG.^[@R7],[@R8],[@R9]^ In brief, an Illumina paired-end pre-capture library was constructed with 1ug of DNA, according to the manufacturer's protocol (Illumina Multiplexing_SamplePrep_Guide\_−1005361_D), with modifications as described in the BCM-HGSC Illumina Barcoded Paired-End Capture Library Preparation protocol.^[@R7]^ Four pre-captured libraries were pooled and then hybridized in solution to the HGSC CORE design (52Mb, NimbleGen) according to the manufacturer's protocol NimbleGen SeqCap EZ Exome Library SR User's Guide (Version 2.2), with minor revisions. Sequencing was performed in paired-end mode with the Illumina HiSeq 2000 platform, with sequencing-by-synthesis reactions extended for 101 cycles from each end with an additional cycle for the index read. With a sequencing yield of 12 Gb, 92% of the targeted exome bases were covered to a depth of 20X or greater. Illumina sequence analysis was performed with the HGSC Mercury analysis pipeline (<https://www.hgsc.bcm.edu-/software/mercury>), which moves data through various analysis tools from the initial sequence generation on the instrument to annotated variant calls (SNVs and intra-read indels). Variant interpretation was performed according to the most recent guidelines published by the American College of Medical Genetics and Genomics (ACMG).^[@R10]^ Accordingly, only variants that met strict criteria were called pathogenic. Sanger sequencing confirmed all variants reported in this paper.

Whole mount *in situ* hybridization {#S9}
-----------------------------------

Digoxygenin-11-UTP-labeled antisense RNA probe for *dyrk1a* was synthesized *in vitro* from *Xenopus* Genome Collection IMAGE clone 7687837 ^[@R11]^ using SalI restriction enzyme and T7 polymerase. This clone carries the *Xenopus tropicalis* coding sequence for *dyrk1a*, therefore, both *X. tropicalis* and *X. laevis* embryos were stained to ensure proper detection of the target. Embryos were staged, fixed, and stained according to standard procedures^[@R12],[@R13]^ using an anti-digoxygenin antibody (1:3000, Sigma 11093274910, St. Louis MO, USA) and BM Purple (Sigma 11442074001, St. Louis MO, USA).

*Xenopus laevis* embryos and microinjections {#S10}
--------------------------------------------

*Xenopus* eggs were obtained by standard means, placed in 0.3x MMR and fertilized *in vitro*.^[@R13]^ Blastula cleavage stages and dorsal versus ventral polarity were determined by established methods.^[@R12]^ Microinjections were targeted to the V2 blastomere at the eight-cell stage, which provides major contributions to the development of the pronephros.^[@R12],[@R14],[@R15]^ Ten nL of injection mix (described below) was injected into embryos. Ten ng of Dyrk1a morpholino 5'-TGCATCGTCCTCTTTCAAGTCTCAT-3′^[@R16]^ or Standard morpholino 5′-CCTCTTACCTCAGTTACAATTTATA-3′ was co-injected with 50 pg RNA (either control *β- galactosidase*, wild-type human *DYRK1A*, *DYRK1A* ^*R205\**^ or *DYRK1A* ^*L245R*^) along with 1 ng membrane-RFP RNA^[@R17]^ as a lineage tracer to verify that the correct blastomere was injected. Details about design and statistical analysis are included in [Supplemental Methods](#SD6){ref-type="supplementary-material"}.

Immunostaining {#S11}
--------------

Embryos were staged,^[@R12]^ fixed, and immunostained^[@R18]^ using established protocols. Proximal tubule lumens were labeled with the antibody 3G8 (1:30, European *Xenopus* Resource Centre, Portsmouth, United Kingdom), while the cell membranes of distal and connecting tubules were labeled with antibody the 4A6 (1:5, European *Xenopus* Resource Centre, Portsmouth, United Kingdom).^[@R19]^ Rabbit anti-red fluorescent protein (anti-RFP) (1:250, MBL International, Woburn, MA, USA) antibody was used to detect the RFP tracer. Goat anti-mouse or anti-rabbit conjugated to Alexa Fluor 488 or Alexa Fluor 555 (1:500, Invitrogen, Carlsbad, CA, USA) secondary antibodies were used to visualize antibody staining.

Imaging {#S12}
-------

Embryos used for *in situ* hybridization were imaged on a Zeiss AxioZoom V16 with a 1X objective, Zeiss 512 color camera (Zeiss, Oberkochen, Germany), and extended depth of focus processing. Embryos used for immunostaining were scored and photographed using an Olympus SZX16 fluorescent stereomicroscope and Olympus DP71 camera (Olympus, Toyko, Japan). 3G8/4A6 immunostained kidney images were taken using a Zeiss LSM800 confocal microscope (Zeiss, Oberkochen, Germany). Fixed embryos were cleared with BABB/Murray's clearing solution for confocal imaging (1:2 volume of benzyl alcohol to benzyl benzoate). Images were processed with Adobe Photoshop.

RESULTS {#S13}
=======

CAKUT/GD identified in patients with *DYRK1A* variants {#S14}
------------------------------------------------------

The index patient was seen in Renal Genetics Clinic (RGC) for the evaluation of ID, global DD, hypospadias, and congenital chordee. Trio ES (tES) revealed a novel *de novo* pathogenic p.G168fs single base pair deletion in *DYRK1A*. A subsequent query of the ES database at BG revealed a total of 18 additional individuals with SNVs or deletions ≤10 base pairs (as defined in methods) in *DYRK1A* among approximately 8000 probands. Phenotype and molecular information of these patients are summarized in [Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}. Probands were mostly children ranging from 2 to 27 years of age. All 19 of these individuals had neurodevelopmental phenotypes consistent with loss-of-function of *DYRK1A* \[MIM: 614104\]. We subsequently contacted all referring physicians to obtain further details regarding the CAKUT/GD phenotypes. However, CAKUT/GD statuses of four patients remain unknown. Eleven out of fifteen (73%) individuals with available information presented with CAKUT including unilateral renal agenesis (URA), and/or GD including undescended testis, hypospadias, etc. ([Table 2](#T2){ref-type="table"}). One patient (P6) with URA was identified after this newly acquired association of *DYRK1A* with CAKUT was discussed with the referring physician.^[@R20]^ Probability of loss-of-function intolerance (pLI) score of *DYRK1A* is 1, indicating that this gene is intolerant to loss-of-function variants.^[@R21]^

A majority of the variants found in *DYRK1A* are loss-of-function and are found in the kinase domain. {#S15}
-----------------------------------------------------------------------------------------------------

Many of the variants found in this cohort are found in the kinase domain \[14 out of 17 (82%)\], which spans from residues 159-479, and 11 out of 17 (65%) are thought to undergo nonsense-mediated decay (NMD), as they result in premature stop codons (<https://nmdpredictions.shinyapps.io/shiny/>) ([Figure 1](#F1){ref-type="fig"}). Of the remaining six variants, one affects splicing, one escapes NMD (p.S494fs), and four are missense variants. The four missense variants are all found in the kinase domain in four individuals. Of these four individuals with missense variants, P7 was diagnosed with URA (p.L245R), P5 and P10 had normal renal ultrasounds (p.V173F and p.G348R), and P17 has an unknown CAKUT status (R467Q). Because these variants still lead to other *DYRK1A*-syndrome features such as ID, they may be important for the catalytic activity or conformational stability of DYRK1A. In fact, in a separate DYRK1A structural study the R467Q variant was found to be a part of a network of electrostatic interactions thought to play a role in the stability of the DYRK1A protein.^[@R22]^ Additionally, the L245R variant was found to prevent autophosphorylation of DYRK1A's activation loop in HEK293 cells^[@R23]^ and was shown to be catalytically inactive via an *in vitro* kinase assay.^[@R24]^ Out of the three variants not found in the kinase domain, two are just N-terminal (N151fs, K154fs) and the last is found just C-terminal (to kinase domain) in the PEST domain (S494fs). Although, theoretically, all variants that are more N-terminal should result in NMD, a majority of the variants reside in the kinase domain for unknown reasons that should be studied further.

*Xenopus laevis* as a model of GU development {#S16}
---------------------------------------------

DYRK1A's amino acid sequence is highly conserved among amniotes (<https://www.ncbi.nlm.nih.gov/homologene>). Even though the N- and C-terminal regions diverge in invertebrates, the amino acid sequence of the kinase domains are similar indicating the importance of this protein throughout evolution. In order to model CAKUT/GD associated with human *DYRK1A* loss-of-function variants using *Xenopus laevis* embryos (hereafter referred to simply as *Xenopus*), we analyzed the conservation of the whole DYRK1A protein sequence, focusing on the kinase domain. Human and *Xenopus* DYRK1A proteins are 91.3% identical over the entire amino acid sequence ([Figure S1A](#SD2){ref-type="supplementary-material"}). Additionally, the kinase domain, which is where a majority of the variants that cause CAKUT/GD (in this study) are found, is 97.5% identical to the human protein ([Figure 1](#F1){ref-type="fig"}). Importantly, the human and *Xenopus* kinase activation loop sequence, which is essential for the kinase activity of DYRK1A, are identical.

*Xenopus* produces large clutch sizes with hundreds of embryos that develop externally, and unilateral embryo injections allow for tissue-targeted knockdowns that are specific to organs such as the kidney.^[@R14]^ Their embryonic kidney, the pronephros, can easily be visualized and imaged through a transparent epidermis, and they develop a fully functional kidney in \~56 hours.^[@R25]^ *Xenopus* was chosen because it is an established model of nephron development, and gene expression studies demonstrate that the developing *Xenopus* nephron is anatomically and functionally similar to the mammalian nephron.^[@R26]-\ [@R28]^ The embryonic pronephros is the precursor to the mesonephric and metanephric kidney in mammals, and subsequent GU development is dependent upon this structure. Specifically, as the pronephros extends toward the cloaca, the mesonephric nephrons form adjacent to the elongating nephric duct, also known as the Wolffian duct.^[@R29]^ The ureteric bud, which is required for the development of the collecting duct system in mammals, then branches from this duct. Because the Wolffian duct is required for GU development in males and Müllerian duct elongation, necessary for normal female anatomy, depends upon the development of the Wolffian duct,^[@R30],[@R31]^ the development of the pronephros is critical to both renal and genital development in mammals. Thus, although it is not a well-established model for studying genital formation, the *Xenopus* pronephros is essential for development of the mesonephric/Wolffian duct and subsequently the Müllerian duct, which are required for GU development.^[@R32],[@R33]^

*dyrk1a* is expressed in the *Xenopus* kidney and *in vivo* knockdown demonstrates its role in kidney development. {#S17}
------------------------------------------------------------------------------------------------------------------

To assess whether *dyrk1a* is expressed in the *Xenopus* kidney, *in situ* hybridization was performed across developmental stages in both *X. laevis* and *X. tropicalis* ([Figure 2](#F2){ref-type="fig"}). *dyrk1a* expression is seen in the pronephros in several stages of both *X. laevis* and *X. tropicalis* embryos during kidney development, suggesting that it may be important for nephrogenesis.

To examine *dyrk1a*'s role in renal development in *Xenopus laevis*, an anti-sense morpholino (MO) that blocks translation was used to knock down endogenous Dyrk1a protein expression. *Xenopus laevis* has two copies of the *dyrk1a* gene because of its allotetraploid genome. Both *dyrk1a* transcripts are targeted by the Dyrk1a MO used in this study ([Figure S1B](#SD2){ref-type="supplementary-material"}). Western blot analysis was used to confirm that the MO correctly targets *Xenopus dyrk1a* RNA ([Figure S2B](#SD3){ref-type="supplementary-material"}). Knockdown experiments were used to determine whether loss of Dyrk1a function in *Xenopus* results in disruption of kidney development. Embryos were injected in a single V2 blastomere to target a single kidney, leaving the other as an internal control. Knockdown with a Dyrk1a MO resulted in abnormal pronephroi when immunostained with antibodies 3G8 and 4A6, which label the proximal tubules and the distal and connecting tubules (nephric duct), respectively ([Figure 3B](#F3){ref-type="fig"}). Loss of Dyrk1a primarily affected the proximal and distal tubules, with defects in the connecting tubules (nephric duct) occurring only in embryos with a more severe phenotype.

Variants identified in *DYRK1A*-related ID syndrome fail to rescue Dyrk1a loss-of-function in *Xenopus.* {#S18}
--------------------------------------------------------------------------------------------------------

To assess if patient *DYRK1A* variants lead to pronephric anomalies as they do in *Xenopus*, rescue experiments were carried out upon MO-mediated Dyrk1a knockdown in *Xenopus.* To express human *DYRK1A* in *Xenopus,* three constructs with HA tags were generated: wild-type human *DYRK1A*, a truncating patient variant *DYRK1A*^*R205\**^, and a missense patient variant *DYRK1A*^*L245R*^. Western blot analysis was used to confirm that the wild-type human *DYRK1A* and *DYRK1A*^*L245R*^, \~95 kDa, and the truncated human *DYRK1A*^*R205\**^ RNA constructs, \~25 kDa, could be successfully expressed in *Xenopus* ([Figure S2C](#SD3){ref-type="supplementary-material"}). Overexpression of the rescue dose (50pg) of either *β-galactosidase (β-gal)*, wild-type *DYRK1A*, *DYRK1A*^*R205\**^ or *DYRK1A*^*L245R*^ RNA demonstrated no gain-of-function phenotype of either *DYRK1A* variant ([Figure S3](#SD4){ref-type="supplementary-material"}). The kidney anomalies caused by Dyrk1a knockdown were partially rescued by co-injecting wild-type human *DYRK1A* RNA ([Figure 3C](#F3){ref-type="fig"}). However, neither *DYRK1A* ^*R205\**^ or *DYRK1A*^*L245R*^ RNA rescued these anomalies ([Figure 3D](#F3){ref-type="fig"}-[E](#F3){ref-type="fig"}). Detailed descriptions of how embryos are scored can be found in [Figure S4](#SD5){ref-type="supplementary-material"}.

To assess whether Dyrk1a depletion affects kidney function, an assay was performed evaluating edema formation.^[@R18]^ Edema can be caused by a disruption in the kidneys' ability to excrete excess fluid, but it can also be caused by heart or liver failure. Both the heart and liver arise from dorsal cells in Xenopus ([Xenbase.org](http://Xenbase.org)). To prevent knockdown in these tissues, embryos were injected with Dyrk1a MO or Standard MO in both ventral cells at the four-cell stage to affect both kidneys. Embryos injected with the Dyrk1a MO suffered from edema and abnormal kidneys, characterized by swelling in the chest cavity due to fluid retention ([Figure 3I](#F3){ref-type="fig"}) while embryos injected with the Standard MO did not ([Figure 3H](#F3){ref-type="fig"}). This technique suggests that loss of *dyrk1a* affects kidney function in *Xenopus*. Taken together, these data support a role for DYRK1A in pronephric development and strongly suggest that the *DYRK1A*^*R205\**^ and *DYRK1A*^*L245R*^ variants are responsible for the kidney anomalies observed in these patients.

DISCUSSION {#S19}
==========

Recent discoveries demonstrate that *de novo* pathogenic variants in *DYRK1A* cause a syndromic form of ID \[OMIM: 614104\]. The findings in the current study indicate that CAKUT/GD should be included as features associated with this syndrome.

CAKUT consist of a heterogeneous clinical spectrum, and how CAKUT arise is largely unknown. Thus, it is important to identify all genes and causal variants involved.^[@R34]^ Strong genetic causality of monogenic disease only accounts for 14% of CAKUT cases,^[@R35]^ and polygenic causes are speculated to occur but are largely unknown.^[@R36]^ Next-generation sequencing, specifically ES, has improved the discovery of novel causative genes that are important in GU development.^[@R37]-[@R39]^ Here, we report on a novel genetic contribution of *DYRK1A* to CAKUT/GD. We identified 17 unique variants in *DYRK1A* from clinical ES in 19 unrelated individuals. As summarized in [Table 1](#T1){ref-type="table"}, microcephaly, ID, DD, and seizure are some of the more common features of this syndrome.

Eleven out of fifteen (73% of those with available data) individuals in this study ([Table 2](#T2){ref-type="table"}) have CAKUT/GD, with 36% having renal anomalies, in addition to other organ involvement. While renal anomalies have been reported previously,^[@R20]^ broadly based phenotyping for CAKUT was not performed in previous studies.

Seven of the *DYRK1A* variants identified in our study were novel as they were absent in ClinVar as well as gnomAD/ExAc databases. Per inclusion criteria, most of *DYRK1A* variants were *de novo* and included truncating variants. This suggests a loss-of-function mechanism for variants causing this syndrome which further supports the findings of another group who proposed reduced kinase function as the cause.^[@R22]^

In addition, we determined that *dyrk1a* is expressed in the developing *Xenopus* kidney and found that *dyrk1a* knockdown results in abnormal tubules or complete loss of the kidney. This phenotype could be partially rescued by human *DYRK1A* RNA. However, a nonsense (R205\*) and a missense (L245R) variant failed to rescue the phenotype, indicating that loss-of-function variants in this gene are likely causative for the observed phenotype in some patients. This suggests that DYRK1As kinase domain may be important for kidney development. Furthermore, Dyrk1a MO was injected into two cells to affect both kidneys, which resulted in edema suggesting that Dyrk1a is important for both kidney development and function. Although *Xenopus* is an established model to study kidney development, it has not been commonly used to study GD. However, our findings related to pronephric development are likely relevant to the mammalian GU tract, given the dependence of the formation of the male and female urogenital tract upon the nephric duct and the pronephros.

One limitation of this study is that we were not able to obtain GU information from all patients. Future plans for research include identification and studying the phenotype and underlying variants in a larger number of affected families. Furthermore, signaling pathways involved in *DYRK1A*-related CAKUT/GD should be investigated.

In summary, the phenotype of *DYRK1A*-related ID syndrome is expanded to include CAKUT/GD. Based on our data, we empirically recommend that individuals with DYRK1A syndrome undergo a renal ultrasound and a thorough genital physical exam.
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======================
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![CAKUT associated with *DYRK1A* variants in patients with *DYRK1A*-related intellectual disability syndrome.\
Schematic shows the DYRK1A protein domains. Shapes, which identify the type of variant (squares=frame shift variants, circles=missense variants, stars=nonsense variants, triangles=splice variants), are positioned where *DYRK1A* patient variants impact the amino acid sequence. Patient variants are labeled by patient number as listed in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Variants that result in CAKUT are red, those that do not result in CAKUT are blue, and those in which the effects on CAKUT status are unknown are black. Protein domains are abbreviated as follows: NLS=nuclear localization signal, DH=DYRK homology box, PEST= proline (P), glutamic acid (E), serine (S), and threonine (T), HIS=histidine and Ser/Thr=Serine/Threonine. Inset shows highly conserved sequence surrounding the activation loop (labeled in orange) of the kinase domain.](nihms-1536030-f0001){#F1}

![*In situ* hybridization of *dyrk1a* across developmental stages demonstrates kidney expression in *X. laevis* and *X. tropicalis.*\
To demonstrate spatial-temporal expression of *dyrk1a* in the kidney, *in situ* hybridization was performed. Given that the RNA probe was designed against the *X. tropicalis* sequence, both species were analyzed. Pronephric kidney development occurs between stages 12.5-40. Expression of *dyrk1a* can be visualized in stage 31-40 embryos suggesting Dyrk1a may be important for kidney development. For clarity, insets (D' and J') for stage 30/31 tadpole kidneys with 200μm scale bars have been added. All other scale bars represent 1000μm.](nihms-1536030-f0002){#F2}

![Loss of Dyrk1a affects kidney development in *Xenopus laevis.*\
(A-E') Embryos were unilaterally injected at the 8-cell stage with 10ng of Dyrk1a MO or Standard MO (Std MO) along with 50 pg *β-gal*, wild-type, *DYRK1A*^*R205\**^, or *DYRK1A*^*L245R*^ RNA. Stage 40 tadpoles were stained with kidney antibodies 3G8, which label the proximal tubules and 4A6, which labels the distal and connecting tubules. Letters without apostrophes (A-E) represent the injected side, whereas letters with apostrophes (A'-E') represent the uninjected side. (B) Knockdown with a translation-blocking Dyrk1a MO disrupts kidney development which can be partially rescued (C) by co-injecting with wild-type human *DYRK1A* RNA but not (D-E) *DYRK1A*^*R205\**^ or *DYRK1A*^*L245R*^ RNA. (A) Co-injection of a Standard MO and β-gal serve as a negative control. Scale bars represent 100 μm. (F) The graph demonstrates a significant difference between embryos injected with either Dyrk1a MO + *β-gal* or Dyrk1a MO + *DYRK1A*^*R205\**^ versus with Dyrk1a MO + *DYRK1A* suggesting successful rescue with human *DYRK1A* but not with the nonsense RNA. (G) The second graph demonstrates a significant difference between embryos injected with Dyrk1a MO + *DYRK1A*^*L245R*^ versus with Dyrk1a MO + *DYRK1A,* which suggests that the missense RNA also fails to rescue. Significance was established against embryos that had a moderate or severe kidney phenotype (orange bar) and excluded embryos that had a weak phenotype (yellow bar). (F) \* (asterisk) = p\<0.001 comparing individual experimental groups to Standard MO + *β-gal*. \# (pound sign) = p\<0.006 comparing Dyrk1a MO + *DYRK1A* to Dyrk1a MO + *DYRK1A*^*R205\**^. (G) \* (asterisk) = p\<0.001 comparing Standard MO + *β-gal* to Dyrk1a MO + *β-gal* or Dyrk1a MO + *DYRK1A*^*L245R*^. \# (pound sign) = p\<0.05 comparing Dyrk1a MO + *DYRK1A* to Dyrk1a MO + *DYRK1A*^*L245R*^. For edema assays, embryos were injected at the 4-cell stage in both ventral cells to target both kidneys while avoiding the dorsal cells fated to become the heart and liver, which can also lead to edema. (H) Embryos injected with the Standard MO did not develop edema while embryos injected (I) with the Dyrk1a MO did develop edema and also suffered from abnormal kidney formation. (J) The graph demonstrates a significant difference in edema and kidney abnormalities in embryos injected with either Standard MO or Dyrk1a MO. \* (asterisk) = p\<0.008 comparing Standard MO to Dyrk1a MO embryos with edema, defects in one, and defects in both kidneys. Error bars represent standard error. For ease of comparison of (n) and p-values across conditions, please refer to [Table S1](#SD7){ref-type="supplementary-material"}-[3](#SD7){ref-type="supplementary-material"}.](nihms-1536030-f0003){#F3}

###### 

Demographics, molecular data, and phenotype of 19 patients with SNVs and small indels (\<10bp) in *DYRK1A* identified by clinical exome sequencing

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient\                              Age\      Gender   Ethnicity        Nucleotide\      AA\        Novel\    DF/\    FD    Microcephaly   Seizures   ID    DD    Renal/\   ASD
  number                                (years)                             change           change     Variant   FTT                                                 GU        
  ------------------------------------- --------- -------- ---------------- ---------------- ---------- --------- ------- ----- -------------- ---------- ----- ----- --------- -----
  P1[\*](#TFN2){ref-type="table-fn"}    2.3       F        Caucasian        c.452dupT        p.N151fs   −         \+      \+    \+             −          ukn   M,S   \+        ukn

  P2[\*](#TFN2){ref-type="table-fn"}    3.3       M        Caucasian        c.461delA        p.K154fs   −         **+**   \+    \+             \+         \+    M,S   \+        \+

  P3                                    9.5       F        Caucasian        c.489_495del     p.L164fs   \+        **+**   \+    \+             \+         \+    M,S   \+        \+

  P4                                    11        M        Hispanic         c.501delA        p.G168fs   \+        **−**   \+    \+             \+         \+    G     \+        ukn

  P5                                    2         M        Caucasian        c.517G\>T        p.V173F    \+        **+**   \+    \+             \+         ukn   S     nRUS      ukn

  P6[\*](#TFN2){ref-type="table-fn"}    5.1       M        Not specified    c.613C\>T        p.R205X    −         **−**   \+    \+             −          ukn   U     \+        \+

  P7[\*](#TFN2){ref-type="table-fn"}    7         F        Vietnamese       c.734T\>G        p.L245R    −         **−**   \+    \+             −          \+    M,S   \+        ukn

  P8                                    20.5      M        Caucasian        c.787C\>T        p.R263X    −         **+**   \+    \+             \+         \+    M,S   \+        \+

  P9                                    5.7       M        Caucasian        c.986_995del     p.S329fs   \+        **+**   \+    \+             \+         \+    G     \+        \+

  P10                                   9.8       M        Middle Eastern   c.1042G\>A       p.G348R    \+        **−**   \+    ukn            \+         \+    G     nRUS      ukn

  P11                                   13.5      M        Not specified    c.1098+1G\>A     N/A        −         **−**   \+    \+             \+         ukn   G     ukn       \+

  P12                                   27.1      M        Not specified    c.1162dupG       p.A388fs   −         \+      ukn   \+             \+         \+    G     \+        ukn

  P13                                   14.8      F        Not specified    c.1217_1220del   p.K406fs   \+        **+**   ukn   ukn            \+         ukn   M     ukn       \+

  P14                                   13.8      F        Not specified    c.1309C\>T       p.R437X    −         **−**   ukn   \+             −          \+    M,S   ukn       ukn

  P15                                   10.1      F        Hispanic         c.1309C\>T       p.R437X    −         **−**   \+    \+             \+         ukn   S     nRUS      ukn

  P16                                   5.7       F        Filipino         c.1309C\>T       p.R437X    −         **−**   \+    \+             \+         \+    G     nRUS      ukn

  P17                                   19.6      F        Caucasian        c.1400G\>A       p.R467Q    −         **+**   \+    \+             −          \+    G     ukn       ukn

  P18[\*](#TFN2){ref-type="table-fn"}   18.5      M        Caucasian        c.1399C\>T       p.R467X    −         **−**   \+    \+             \+         \+    M,S   \+        \+

  P19                                   9.4       M        Hispanic         c.1478dupT       p.S494fs   \+        ukn     \+    \+             \+         \+    M,S   \+        \+
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ASD: Autism spectrum disease (HP:0000717), DD: Developmental delays; Global (G; HP:0001263), Motor (M; HP:0001270), Speech (S; HP:0000750), Unspecified (U), DF/FTT: Difficulty feeding (HP:0011968)/ failure to thrive (HP:0001508), FD: Facial dysmorphism (HP:0001999), GU: Genitourinary; Normal renal ultrasound nRUS, Unknown ukn, + denotes phenotype observed (see [Table 2](#T2){ref-type="table"} for more details), ID: Intellectual disability (HP:0001249)

denotes published patients^[@R20]^

###### 

Available information about genitourinary (GU) phenotype of patients reported in this study. Eleven patients have GU phenotype. This strongly suggests an important role for DYRK1A in GU tract development.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case\    SNV            Segregation                                     Renal or GU Phenotype
  Number                                                                  
  -------- -------------- ----------------------------------------------- --------------------------------------------------------------------------------------------
  P1       p.N151fs       Mother negative, father\'s sample unavailable   **Mild unilateral pelviectasis (HP:0010946) and frequent UTIs (HP:0000010)**

  P2       p.K154fs       *De Novo*                                       **Genital anomalies (HP:0000078)**

  P3       p.L164fs       *De Novo*                                       **Kidney abnormalities (not specified; HP:0000077)**

  P4       p.G168fs       *De Novo*                                       **Hypospadias (HP:0000047), micropenis (HP:0000054), and congenital chordee (HP:0000041)**

  P5       p.V173F        *De Novo*                                       Renal ultrasound is normal with normal genitalia on exam

  P6       p.R205X        *De Novo*                                       **Left renal agenesis (HP:0000122)**

  P7       p.L245R        *De Novo*                                       **Left renal agenesis (HP:0000122)**

  P8       p.R263X        *De Novo*                                       **Shawl scrotum (HP:0000049) and history bilateral orchiopexy (HP:0000028)**

  P9       p.S329fs       *De Novo*                                       **Hypospadias (HP:0000047) and kidney abnormalities (tiny echogenic foci)**

  P10      p.G348R        *De Novo*                                       Normal renal ultrasound

  P11      c.1098+1G\>A   *De Novo*                                       Unknown

  P12      p.A388fs       Mother negative, Father is mosaic               **Frequent UTI (HP:0000010)**

  P13      p.K406fs       *De Novo*                                       Unknown

  P14      p.R437X        *De Novo*                                       Unknown

  P15      p.R437X        Mother negative, father\'s sample unavailable   Normal renal ultrasound

  P16      p.R437X        *De Novo*                                       Normal renal ultrasound

  P17      p.R467Q        *De Novo*                                       Unknown

  P18      p.R467X        *De Novo*                                       **Orchiopexy (HP:0000028) and inguinal hernia** (**HP:0000023)**

  P19      p.S494fs       *De Novo*                                       **Bilateral inguinal hernias (HP:0000023)** but no renal ultrasound
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
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